Enterotoxemia Type D Vaccination Of Lambs

December 09, 1997

ITHACA, N.Y. -- Young lambs may not need inoculation against enterotoxemia type D -- otherwise known as "overeating disease" -- until past the age of 6 weeks, according to Cornell University animal scientists.

Enterotoxemia type D often occurs when sheep and cattle are fed high-grain diets. The disease is of major economic concern in livestock production systems.

The Cornell scientists examined sets of triplet lambs from ewes that either were or were not vaccinated at 3 weeks prior to lambing. One lamb in each set was not vaccinated. Another lamb was vaccinated at birth and three weeks. The third lamb was vaccinated at 3 and 6 weeks.

The result: The lamb vaccination schedules had no effect on antibody response to enterotoxemia type D. However, lambs from vaccinated ewes had much higher levels of antibodies than those from unvaccinated ewes. "The ewes provide a lot of antibodies through the colostrum, which is passed along to the lambs," said Thonney. "Now we know that it is not necessary to vaccinate the lambs until at least 6 weeks of age, especially if the ewes were vaccinated."

Published in the Journal of Animal Science (September 1997), "Vaccination Schedules to Raise Antibody Concentrations Against e-Toxin of Clostridium perfringens in Ewes and Their Triplet Lambs," the study was researched and written by Michael L. Thonney, Cornell professor of animal science; Douglas E. Hogue, Cornell professor emeritus of animal science; and Cristina de la Rosa, M.S. '97, who is back living in Venezuela.

Time-management costs are no small matter in New York or national agriculture. In 1996, there were 55,000 sheep on about 1,800 farms in New York state, while the total American population of sheep is 10 million.

Hogue explains that reducing the number of vaccinations saves time and energy for those who raise farm animals. "If you have a flock of 75 lambs and now you don't have to vaccinate those 75 lambs, that's a significant time saving. It's another step in chore-reduction," Hogue said.


Cornell University

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.